Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update

K Engle, G Kumar - European journal of medicinal chemistry, 2022 - Elsevier
Chemotherapy is one of the most common treatments for cancer that uses one or more anti-
cancer drugs as a part of the standardized chemotherapy regimen. Cytotoxic chemicals …

The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade

RJ Kathawala, P Gupta, CR Ashby Jr, ZS Chen - Drug resistance updates, 2015 - Elsevier
ATP-binding cassette (ABC) transporters represent one of the largest and oldest families of
membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy …

[HTML][HTML] Mechanisms of resistance to EGFR tyrosine kinase inhibitors

L Huang, L Fu - Acta Pharmaceutica Sinica B, 2015 - Elsevier
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

Advances in targeting cyclic nucleotide phosphodiesterases

DH Maurice, H Ke, F Ahmad, Y Wang… - Nature reviews Drug …, 2014 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and
cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides …

Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders

A Samidurai, L Xi, A Das… - Annual review of …, 2023 - annualreviews.org
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …

[HTML][HTML] Pharmacokinetic drug-drug interaction and their implication in clinical management

C Palleria, A Di Paolo, C Giofrè, C Caglioti… - Journal of research in …, 2013 - ncbi.nlm.nih.gov
Drug-drug interactions (DDIs) are one of the commonest causes of medication error in
developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20 …

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

K Natarajan, Y Xie, MR Baer, DD Ross - Biochemical pharmacology, 2012 - Elsevier
Since cloning of the ATP-binding cassette (ABC) family member breast cancer resistance
protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter …

PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer

A Das, D Durrant, FN Salloum, L Xi… - Pharmacology & …, 2015 - Elsevier
Abstract The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™),
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …

Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer

HH Zhou, X Chen, LY Cai, XW Nan, JH Chen… - Frontiers in …, 2019 - frontiersin.org
Overexpression of drug efflux transport ABCB1 is correlated with multidrug resistance (MDR)
among cancer cells. Upregulation of ABCB1 accounts for the recurrence of resistance to …

Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators

IF Zattoni, LC Delabio, J de Paula Dutra, DH Kita… - European journal of …, 2022 - Elsevier
The primary source of failure of cancer therapies is multidrug resistance (MDR), which can
be caused by different mechanisms, including the overexpression of ABC transporters in …